Objectives: Chromosomal rearrangements involving ROS1 define a rare entity of lung adenocarcinomas with exquisite sensitivity to molecularly targeted therapy. We report clinical outcomes and genomic findings of patients with ROS1-positive lung cancer who were prospectively identified within a multiplex biomarker profiling program at the West German Cancer Center.
(two cases), phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene (PIK3CA), and BRAF. Three cases initially classified as ROS1 FISH-negative passed the threshold of 15% positive events when repeat biopsies were analyzed at progression. The median overall survival of the ROS1-positive patients (104 months) was significantly superior to that of the 261 patients with EGFR/anaplastic lymphoma kinase/ROS1-negative lung adenocarcinoma (24.4 months, p ¼ 0.044). Interestingly, the overall survival of the 13 ROS1-positive patients with lung cancer from initiation of pemetrexed-based chemotherapy was significantly prolonged when compared with that of 169 pemetrexed-treated patients with EGFR/ anaplastic lymphoma kinase/ROS1-negative adenocarcinoma (p ¼ 0.01).
Conclusions: ROS1-positive metastatic lung adenocarcinomas frequently harbor concomitant oncogenic driver mutations. Levels of ROS1 FISH-positive events are variable over time. This heterogeneity provides additional therapeutic options if discovered by multiplex biomarker testing and repeat biopsies.
Introduction
NSCLC is the leading global cancer fatality. Although its incidence and mortality have slightly decreased in the male population of developed countries, the figures are sharply rising in the female population and in emerging countries. 1 Still, the majority of patients either have metastatic disease at the time of diagnosis, or, if they did not have metastatic disease at diagnosis, later experience a relapse. These patients benefit from palliative systemic therapies in terms of symptom control, quality of life, and prolonged survival times. 2, 3 Recently, histological subtypes of NSCLC have become appreciated in the selection of systemic therapies. Patients are now grouped as having squamous NSCLC or nonsquamous NSCLC, with adenocarcinomas being by far the largest entity. 4 The definition of NSCLC entities has been further refined by validation of recurrent oncogenic mutations as predictive biomarkers for therapeutically tractable oncogenic dependencies. Genomically stratified front-line therapy with EGFRtargeting agents for patients with EGFR-mutated metastatic lung cancer is firmly established. 5, 6 With the completion of more comprehensive genomic analyses 7 and functional preclinical validation, the list of potentially actionable genomic aberrations in lung cancer is constantly expanding. Although activating EGFR mutations are found in 10% to 50% of patients, depending on the geographic region, more recently nominated oncogene-defined entities are being detected in the singledigit range. 8 This poses a significant challenge to the thorough clinical validation of the power of such mutations as predictive biomarkers. Among those, lung cancers harboring anaplastic lymphoma receptor tyrosine kinase gene (ALK) rearrangements have advanced the most so far, with the demonstration of superior progression-free survival with crizotinib versus standard chemotherapy by prospective phase III studies. 9, 10 Second-generation anaplastic lymphoma kinase (ALK) inhibitors 11, 12 have gained fast-track approval despite still being in late-stage clinical development.
Recently, very impressive activity of crizotinib was reported in patients with ROS1-rearranged lung cancers. 13, 14 Although the responses observed in these single-arm studies seem quite durable, a formal demonstration of superiority to standard of care or a survival benefit from crizotinib therapy is missing. Moreover, much still remains to be learned in terms of clinical and biological characterization of ROS1-positive metastatic lung cancer.
To this end we here present biomarker findings and clinical outcomes of patients with metastatic ROS1-positive advanced or metastatic lung cancer that were identified within a prospective biomarker screening program. We observed an unexpectedly high fraction of ROS1-positive cancers with concomitant oncogenic driver mutations, which was clinically validated in some patients by response to targeted therapy. We further show that formal ROS1 fluorescence in situ hybridization (FISH) positivity based on generally accepted cutoff levels is variable when the results of repetitive tumor biopsies are analyzed. Interestingly, the entire group of patients with ROS1 positivity at immunohistochemical (IHC) analysis exhibits an exceptional sensitivity to pemetrexed-based chemotherapy. These findings point at a considerable level of clonal heterogeneity that may be missed by analysis of small diagnostic biopsy specimens. In consequence, some patients could be deprived of potentially active treatment options if treatment decisions are based on single archival biopsy specimens.
Patients and Methods

Preemptive Biomarker Screening Program
Starting in 2012, all patients with advanced or metastatic cancer potentially eligible for study therapy were offered testing using a comprehensive molecular screening panel 15 upon their first presentation at the Department of Medical Oncology of the West German Cancer Center, which is one of 13 oncology centers of excellence in Germany designated by German Cancer Aid. The certified Lung Cancer Center of the West German Cancer Center is one of the largest in Germany and serves the densely populated Ruhr area. On average, lung cancer is newly diagnosed in close to 1000 patients at the center per year. Histopathological diagnosis was based on the current WHO criteria. 16 It was confirmed in all patients who were referred with an external primary diagnosis. In all, consenting patients' biomarker analyses were carried out using formalin-fixed paraffin-embedded (FFPE) tumor material following a predefined algorithm. 
ROS1 IHC Analysis and FISH
ROS1 IHC analysis was performed using 1-to 3-mmthick whole-mount sections of tumor-containing FFPE blocks. An anti-ROS1 primary antibody (D4D6, rabbit monoclonal [Cell Signaling Technology, Cambridge, UK]) was used at a 1:100 dilution with 40 minutes of incubation time at 37 C preceded by 48 minutes of pretreatment in ethylenediaminetetraacetic acid buffer (pH 8.3). Antibody visualization was carried out with the OptiView DAB IHC Detection Kit (Ventana Medical Systems, Tucson, AZ) following the manufacturer's instructions. All analyses were carried out on a Benchmark Ultra System (Ventana Medical Systems).
For FISH, 4-mm-thick FFPE sections of the same tumorcontaining block were cut, and slides were prepared using a commercially available kit (ZytoLight SPEC ROS1 Dual Color Break Apart Probe [ZytoVision GmbH, Bremerhaven, Germany]) following the manufacturer's instructions. The FISH results were evaluated by the same pathologists (H. R. and S. T.) with close correlation of the site of interest in FISH analysis with the histomorphological features on hematoxylin and eosin-stained slides.
Every case with positive ROS1 staining of any intensity was forwarded for FISH analysis. The FISH results were based on at least 50 evaluable tumor nuclei. In some cases of very limited tumor tissue biopsy specimens, a best effort was made to evaluate all available tumor cell nuclei. A break-apart/split FISH signal was considered positive in the case of red and green split signals with a clear-cut distance of at least one signal diameter. Also, isolated green signals were evaluated as positive events. A cutoff of at least 15% break-apart and/ or isolated green events was used as the threshold for ROS1 FISH positivity. 17 
Clinical Data
Clinical data of patients with ROS1-positive NSCLC were retrieved from the electronic medical documentation system of the University Hospital Essen. Patients with NSCLC who participated in the biomarker screening program and had at least 1 year of clinical follow-up (effectively 2012 to the second quarter of 2014) were used for the ROS1-negative reference group and stratified on the basis of detection of additional actionable genomic alterations (EGFR mutated, ALK rearranged, or EGFR/ALK wild type). Further processing and data analysis were performed on pseudonymized data sets. Data acquisition was in line with relevant legislation and institutional review board guidelines.
Results
Prevalence of ROS1-Positive Pulmonary Adenocarcinoma
Within 3 years, 805 patients with histologically confirmed advanced or metastatic pulmonary adenocarcinoma were among the 1345 patients with cancer who were enrolled in the biomarker screening program. All patients in this cohort were treated and/or received follow-up at the West German Cancer Center. Preemptive ROS1 screening was initiated in the second quarter of 2013. Per physician's request, ROS1 screening was retrospectively added for those patients who had been enrolled before introduction of systematic ROS1 profiling. In total, ROS1 IHC analysis was conducted in 523 patients. Of these, 25 patients (4.8%) showed some extent of specific immunoreactivity and were thus subjected to FISH. Median follow-up was 16.4 months. With a cutoff set at 15% of events, 13 cases (2.5%) were ROS1 FISH-positive, and 12 were ROS1 FISH-negative, including seven borderline-negative cases with 10% to 14% positive events. These numbers potentially include survivorship bias introduced by retrospectively requested ROS1 screening. Prevalence in the intention-to-screen population after introduction of systematic ROS1 profiling was 4.1% for IHC analysis positivity and 2.5% for FISH positivity. Clinical characteristics of ROS1-positive cases are summarized in Table 1 . A short synopsis of the individual clinical courses is given in Supplementary Table 1.
ROS1-Positive Lung Cancers with Concomitant Oncogene Mutations
Of 25 cases with ROS1 positivity at IHC analysis, six involved tumors harboring EGFR mutations, including one with an EGFR mutation plus a PIK3CA mutation, two with a KRAS mutation, and one with a BRAF V600E mutation. This added up to 36% of ROS1 IHC analysispositive cases with concomitant oncogenic driver aberrations. The six EGFR-mutated cases had ROS1 FISH-positive events in 28%, 16%, 14%, 12.5% (26% at repeat biopsy), 6%, and 5% (18% at repeat biopsy) of nuclei. The two KRAS-mutated cases had ROS1 FISHpositive events in 12% (18% at repeat biopsy) and 10% of nuclei, and the BRAF-mutated case had ROS1 FISHpositive events in 10%. When the conventional cutoff of 15% positive FISH signals was applied, five of nine patients thus had formally double-positive driver alterations.
In the ROS1/EGFR double-positive cohort, five patients received treatment with an EGFR-targeting agent (afatinib or erlotinib) and showed an initial response. At data cutoff, patient 01 (16% ROS1 FISH-positive events) had ongoing clinical benefit for 12.8 months and a minor response/stable disease was confirmed by computed tomography imaging. Patients 02 (12% ROS1 FISH-positive events) and 03 (5% ROS1 FISH-positive events) received platinum/pemetrexed-based first-line chemotherapy and erlotinib as second-line treatment. In both cases, the best response to chemotherapy was stable disease. Both patients showed an excellent initial response to second-line erlotinib. After 10.8 months of erlotinib patient 02 experienced leptomeningeal progression. She opted against further systemic therapy and died shortly thereafter. Patient 03 progressed after 10 months of erlotinib. An EGFR T790M resistance mutation was confirmed at repeat tumor biopsy, as was ROS1 FISH positivity (see later). The patient was enrolled in a clinical trial of osimertinib and had stable disease for 9.6 months of the study therapy followed by another progression. At data cutoff, she received programmed cell death 1-directed therapy, with stable disease at 4.6 months. Patient 04, who had a combined ROS1-rearranged (28% ROS1 FISH-positive signals) and EGFR-and PIK3CA-mutated adenocarcinoma, had an ongoing good partial remission while receiving afatinib (8.0 months). Patient 05 (14% ROS1 FISH-positive signals and EGFR mutation) had an ongoing partial remission after receiving afatinib for 3.0 months. In summary, EGFR-dependent lung cancer was validated in five patients with sufficient follow-up by clinical benefit from EGFR-targeting therapy. Thanks to the sustained clinical benefit or availability of alternative established treatment regimens, off-label crizotinib treatment has so far not been required in these patients. A female patient (07) and a male patient (08) harbored KRASmutated adenocarcinomas with concomitant borderline ROS1 FISH results (positive events in 12% and 10% of nuclei). Both patients had a relevant smoking history. These patients experienced a remarkably unfavorable course of disease. Stage IIIB disease was initially diagnosed in patient 07, and she underwent chemoradiotherapy with curative intent. After 11.5 months she experienced local recurrence, which was first treated with pemetrexed and then with crizotinib. No clinical benefit was achieved and the patient died 5 months after diagnosis of relapse. Patient 08 initially presented with stage IV disease. He progressed while receiving first-and second-line chemotherapy with carboplatin/pemetrexed and carboplatin/gemcitabine and died after 4 months. Crizotinib treatment was not covered by his insurance because he did not meet the formal cutoff for FISH positivity.
Another male patient (09) had initially been classified as "all wild type" by Sanger sequencing but showed 10% positive events at ROS1 FISH. The DNA sample was reanalyzed during our next-generation sequencing validation process, which revealed a BRAF V600E mutation. He received first-line treatment with cisplatin/pemetrexed followed by pemetrexed maintenance for 22 months. After progression, he received docetaxel/ nindetanib (8.1 months at data cutoff).
Robustness of ROS1 FISH Positivity at Repeated Analyses
We applied the distribution of the percentage of positive events at ROS1 FISH to assign the cases with positive ROS1 IHC analysis to three groups ( Fig. 1): (1) 5% or less FISH-positive nuclei, which is equivalent to zero, one, or two positive nuclei when counting 50 nuclei (n ¼ 5); (2) an intermediate group with 10% to 30% FISH-positive nuclei (n ¼ 11); and (3) at least 50% FISHpositive nuclei (n ¼ 9). In the intermediate group (group 2), four cases (36%) were formally FISH-positive when the accepted cutoff of at least 15% positive events was applied.
In four patients (Table 2) we were able to perform a second ROS1 FISH analysis on repeat tumor biopsy 
Survival and Response to Therapy
Overall survival (OS) of the entire ROS1 IHC analysispositive cohort (n ¼ 25) was significantly superior (p ¼ 0.044) to that of an EGFR/ALK-negative control population (n ¼ 261 [ Fig. 2A] ). When patients with less than 15% ROS1 FISH-positive events and patients with concomitant oncogene mutations were excluded, OS of the purely ROS1-positive patients (n ¼ 11) remained superior to that of the EGFR/ALK-negative control group (p ¼ 0.036 [ Fig. 2B]) .
So far, 24 ROS1-positive patients have received at least one line of systemic treatment, 22 of them also in the setting of metastatic or recurrent disease. Thirteen patients were treated with a pemetrexed-containing regimen. Interestingly, OS starting from initiation of pemetrexed-based therapy (any line) of ROS1-positive patients (according to IHC analysis or FISH) was significantly superior (p ¼ 0.01) to that of a control cohort of 169 EGFR/ALK-negative, pemetrexed-treated (any line) patients (Fig. 1C) . When compared with a group of 17 pemetrexed-treated patients with EGFR-mutated lung cancer, the ROS1-positive patients seemed to have superior OS after initiation of pemetrexed. However, at the time of data cutoff statistical significance could not be formally established (p ¼ 0.47 [ Fig. 2C] ). Similar findings were revealed when the focus was on those 11 purely ROS1-positive patients (data not shown). When the IHC analysis-positive cohort was split by FISH positivity (>15% vs. <15% positive events), there was no trend toward better survival in either group (hazard ratio ¼ 0.76, p ¼ 0.75). Supplementary Table 2 provides additional OS data for different subgroups formed according to ROS1 FISH results.
In support of an exceptional sensitivity of ROS1-positive lung cancers to pemetrexed we present five cases, three of which were ROS1 FISH-positive (Table 3) . One female patient 11 exhibited a striking progression-free survival of 54.9 months while receiving pemetrexed maintenance therapy. After a treatment holiday, steady multilocular disease progression was documented. At this point, her tumor was found to be ROS1 FISH-positive at a requested reanalysis, and crizotinib therapy was initiated. The patient experienced a very profound response (Fig. 3) and received crizotinib for 29.0 months. Isolated progression of a pulmonary metastasis was managed by radiotherapy. She recently died from symptomatic intracerebral disease progression while receiving crizotinib (OS 8.7 years).
In total, nine ROS1-positive (all IHC analysispositive/FISH-positive) patients received crizotinib, usually as second-or third-line therapy. Six patients experienced a radiological and clinical response; four are still receiving treatment (median 12.7 months). Three patients had early progression, including patient 07 (with a concomitant KRAS mutation) and patient 10 (who received a brief course of crizotinib as last-line treatment for advanced leptomeningeal disease). The third patient (identifier 15), a young woman, truly had treatment-refractory disease with progression while receiving first-line cisplatin/paclitaxel and second-line crizotinib. She did not receive third-line therapy (see Supplementary Table 1 for details).
Discussion
Treatment options for patients with metastatic lung adenocarcinomas have been greatly expanded by the introduction of targeted therapies that are applied on the basis of detection of predictive genomic biomarkers. Mutations in EGFR, BRAF, erb-b2 receptor tyrosine kinase 2 gene (HER2), and MNNG HOS Transforming gene (MET) indicate therapeutically tractable "oncogenic dependencies" in lung cancer. 5, [18] [19] [20] [21] In addition to EGFR mutation testing, which is the standard of care, many cancer centers routinely screen for these additional mutations to provide further therapeutic options to their patients. Advances in sequencing technology have fostered this development. 22 Chromosomal rearrangements leading to fusion proteins with deregulated kinase activity have been initially described as oncogenic events in the hematopoietic system. 23, 24 More recently, it has become appreciated that such aberrations can act as oncogenic drivers in lung cancer, with ALK rearrangements being one example with extensive clinical validation. The first descriptions of chromosomal rearrangements involving ROS1 in lung cancer were published in 2007 25 and 2012. 17, 26 ROS1 is an "orphan" receptor tyrosine kinase of the insulin receptor family. The gene was first discovered as the homologue of a viral oncogene. 27 The ROS1 receptor has no known ligand, 28 and there is only limited knowledge of its physiological function. 29 Increased expression of ROS1 fusion proteins in consequence of chromosomal rearrangements is observed in several cancers, including glioblastoma, cholangiocarcinoma, and ovarian cancer.
In oncogenic fusion transcripts ROS1 retains its kinase domain, which is thus aberrantly expressed and constitutively active to trigger downstream signaling pathways, including mitogen-activated protein kinase and phosphatidylinositol-4,5-bisphosphate 3-kinase/AKT/ mammalian target of rapamycin pathway. 17 Thanks to the availability of an agent with ROS1-inhibitory activity, crizotinib, initial clinical validation of ROS1 as a therapeutic target in lung cancer was extremely rapid. 13, 14, 17 A break-apart FISH assay was developed for clinical implementation of ROS1 diagnostics following the example of ALK-positive lung cancer, and the cutoff for ROS1 FISH positivity was generally set as at least 15% positive events. 17 On the basis of retrospective studies conducted in lung cancer biobanks largely based on resected early-stage lung cancers, the prevalence of ROS1-positive cases is estimated to be less than 2%. 17, 26, 30 The actual prevalence in the therapeutically relevant population with stage IV lung adenocarcinomas may differ. Nevertheless, ROS1 FISH-positive lung cancers represent a very rare entity. This poses significant challenges in the introduction of systematic screening programs in terms of resources and tissue requirements. Against this background, alternative detection methods have been developed that can be more easily incorporated into the routine diagnostic work-up. IHC detection of ROS1 expression by cancer cells is such an alternative, and it has been rapidly taken up by several centers and screening programs. 31 Suitable primary antibodies are available and have been extensively validated. [32] [33] [34] [35] [36] In our prospectively conducted single-center biomarker screening program we decided to implement a two-step process based on ROS1 IHC analysis prescreening followed by FISH. In our experience (see Supplementary Table 1) , we see no correlation between ROS1 expression level at IHC analysis and FISH results. Therefore, we subject all cases with any ROS1 IHC analysis positivity to FISH. ROS1 FISH results of our IHC analysis-positive cohort revealed a significant level of heterogeneity, which was not entirely unexpected in light of the small tumor biopsy specimens submitted for diagnostic work-up of most patients with stage IV lung cancer. Apart from methodological variance and intratumoral spatial heterogeneity, the finding of increasing FISH ratios in three cases after progression could represent tumor evolution as a result of the selective pressure of anticancer treatment. In particular, the two EGFR/ROS1 double-positive cases demonstrated an expansion of the ROS1-positive clone during EGFRtargeted therapy.
Interestingly, the group of patients with ROS1 IHC analysis positivity showed an exceptional sensitivity to pemetrexed-based chemotherapy. Because of a lack of the necessary control groups, the data are statistically insufficient to establish ROS1 IHC analysis positivity as a predictive factor for treatment response to pemetrexed; yet, they are in line with previous case series of remarkable responses to pemetrexed in ROS1 FISHpositive patients. 14, [37] [38] [39] It may thus be postulated that ROS1-expressing tumors (as demonstrated by IHC analysis and also including cases with less than 15% positive events at FISH) belong to a clinically and biologically distinct lung cancer entity. The introduction of hybrid capture-based sequencing for more comprehensive characterization of oncogenic translocations may help to better define this population. 40, 41 However, predictive cutoffs for this new technology will also have to be clinically validated.
More surprising was the high fraction of patients with concomitant oncogene mutations, which were detected in one-third of ROS1-positive lung cancer cases. Similar findings were reported in a systematic analysis of ALKpositive lung cancers, 42 albeit at much lower frequency. A recent retrospective next-generation sequencing-based reanalysis of tumor tissue samples from 17 selected patients with ROS1-positive lung cancers revealed concurrent tumor protein p53 gene (TP53) mutations in seven cases, two cases with BRAF mutations, and a single case with EGFR mutation. None of these concomitant mutations was clinically validated by response to targeted therapy. 38 Although it was initially thought that oncogenic drivers in lung cancer are mutually exclusive, 43 current studies such as ours applying multiplex biomarker panel testing demonstrate a much higher rate of concomitant potential driver oncogene mutations in advanced lung cancers. [44] [45] [46] This may reflect the higher sensitivity of modern diagnostic technology as well as the representation of clonal heterogeneity, which has been convincingly demonstrated by parallel comprehensive genomic analyses of multiple tumor specimens from the same patients. 47, 48 Importantly, we could unambiguously validate the relevance of concomitant EGFR mutations in five patients by their sustained responses to EGFR-targeting agents. The clinical relevance of the accompanying ROS1 alteration remains unclear at this point: two patients with an expanded ROS1-positive clone at repeat biopsy have already died. They experienced symptomatic intracerebral tumor progression and were no longer suitable for systemic cancer therapy. The other double-positive patients are still benefiting from EGFR-targeting treatment.
One may speculate whether ROS1-rearranged and EGFR-mutated lung cancer clones originate from a common precursor lesion, which if successfully defined could have important implications for prevention and early detection of lung cancer, in particular in nonsmokers. Further, our observations support the evolving strategy to systematically obtain and reanalyze specimens from repeat tumor biopsies at clinical progression at least in patients with lung cancer with confirmed tractable oncogenic driver lesions. This procedure has high potential to identify additional therapeutic options for some patients, which would be overlooked by just focusing on the comprehensive characterization of a biopsy specimen taken at a single time point. It remains to be shown whether multiplex genomic analyses of circulating tumor DNA become sufficiently robust and
